This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Enbrel
  • /
  • Comparative Efficacy and Safety Study of GP2015 an...
Clinical trial

Comparative Efficacy and Safety Study of GP2015 and Enbrel� in Patients With Rheumatoid Arthritis (EQUIRA)

Read time: 3 mins
Last updated:27th Nov 2015
Identifier: NCT02638259

Brief Summary:
Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX).


Detailed Description:
Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX). In addition, data on the safety profiles of both products, including immunogenicity and local tolerability at the injection sites, will be collected and compared.

An additional study objective is to identify any potential risk of the transition from Enbrel to GP2015 in terms of general safety and immunogenicity in RA patients


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 376 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis
Study Start Date: November 27, 2015
Actual Primary Completion Date: December 29, 2016
Actual Study Completion Date: June 12, 2017

Arm:
- Experimental:
50mg GP2015
- Active Comparator: 50mg EU-authorized Enbrel

Category Value
Date last updated at source 2018-02-23
Study type(s) Interventional
Expected enrolment 376
Study start date 2015-11-27
Estimated primary completion date 2016-12-29

View full details